Sinopharm Refutes Claim Of Increasing Stake In Sinopharm Medicine Holding
This article was originally published in PharmAsia News
In response to a China Times article that said Sinopharm plans to increase its stake in Sinopharm Medicine Holding by 30 percent, which would delay the latter's listing in Hong Kong, Sinopharm has issued a statement refuting the claim. It denied seeking approval from relevant authorities for the move. Fosun Pharma, the second largest shareholder of Sinopharm Medicine Holding, also released an announcement rejecting the report published on March 18. (Click here for more - Chinese Language)
You may also be interested in...
Procter & Gamble, through its UK wellness subsidiary Nature's Best, is on-trend with new vegan vitamin D3 and iron supplements. Nature's Best has also launched three other vitamin D3 products in the country, as well as an ashwagandha supplement.
The MHRA has updated its guidance on regulatory flexibilities for medical devices and medicinal products resulting from COVID-19 to highlight how its approach differs from the EU.
The Swiss company is planning a US trial of CBSO, the first transcatheter septal occluder with a bioresorbable, metal-free frame.